Title : Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.

Pub. Date : 2017 Dec 28

PMID : 29042365






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ruxolitinib inhibited 2 major DSB repair mechanisms, BRCA-mediated homologous recombination and DNA-dependent protein kinase-mediated nonhomologous end-joining, and, when combined with olaparib, caused abundant accumulation of toxic DSBs resulting in enhanced elimination of MPN primary cells, including the disease-initiating cells from the majority of patients. ruxolitinib BRCA1 DNA repair associated Homo sapiens